Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/19420862.2020.1782600 http://scihub22266oqcxt.onion/10.1080/19420862.2020.1782600 32546047!7531491!32546047     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       MAbs 2020 ; 12 (1): e1782600 Nephropedia Template TP {{tp|p=32546047|t=2020. Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic |pdf=|usr=}}{{32546047}} gab.com Text Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic JO: MAbs http://www.kidney.de/pget.php?&tw=1&pmid=32546047 #FOAvip While the potential therapeutic utility of angiotensin-converting enzyme 2 (ACE2) is well established, the clinical development of ACE2 drugs has been limited, likely due in part to the short half-life of the protein. In contrast, Ig-like ACE2 fusion proteins have exhibited greatly extended plasma half-life in vivo, and they have been shown to have a potent neutralization effect against SARS-CoV-2. Clinical investigation of Ig-like ACE2 fusion proteins as COVID-19 interventions is thus warranted. Twit Text FOAVip Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic ????MAbs http://www.kidney.de/pget.php?&tw=1&pmid=32546047 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32546047 #FOAvip English Wikipedia <ref>{{Cite pmid|32546047}}</ref> Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic #MMPMID32546047 Qian K; Hu S MAbs 2020[Jan]; 12 (1): e1782600 PMID32546047show ga While the potential therapeutic utility of angiotensin-converting enzyme 2 (ACE2) is well established, the clinical development of ACE2 drugs has been limited, likely due in part to the short half-life of the protein. In contrast, Ig-like ACE2 fusion proteins have exhibited greatly extended plasma half-life in vivo, and they have been shown to have a potent neutralization effect against SARS-CoV-2. Clinical investigation of Ig-like ACE2 fusion proteins as COVID-19 interventions is thus warranted. |Angiotensin-Converting Enzyme 2[MESH] |Animals[MESH] |Antiviral Agents/adverse effects/*therapeutic use[MESH] |Betacoronavirus/*drug effects/pathogenicity[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/diagnosis/*drug therapy/immunology/virology[MESH] |Host-Pathogen Interactions[MESH] |Humans[MESH] |Immunoglobulin Fc Fragments/adverse effects/*therapeutic use[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/adverse effects/*therapeutic use[MESH] |Pneumonia, Viral/diagnosis/*drug therapy/immunology/virology[MESH] |Recombinant Fusion Proteins/therapeutic use[MESH] |SARS-CoV-2[MESH]Ig-like ACE2 protein therapeutics: A revival in development during the(epmc).pdf DeepDyve Pubget Overpricing